File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: 48 Weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection

Title48 Weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infection
Authors
Issue Date2006
PublisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APT
Citation
Alimentary Pharmacology And Therapeutics, 2006, v. 23 n. 8, p. 1171-1178 How to Cite?
AbstractBackground/aim: Although 48-week therapy with pegylated-interferons has been shown to be effective for the treatment of chronic hepatitis B virus infection, the efficacy of a shorter duration of therapy with pegylated interferons is unknown. Method: We reviewed 53 hepatitis B e antigen positive Chinese patients treated with 48 weeks of pegylated interferon alpha-2a or 24 weeks of pegylated interferon alpha-2b. Sustained virological response was defined as hepatitis B e antigen seroconversion and hepatitis B virus DNA <105 copies/mL at week 72. Results: Twenty-nine patients were treated with 48 weeks of pegylated-interferon-alpha-2a and 24 patients with 24 weeks of pegylated-interferon-alpha-2b. At the end-of-therapy, hepatitis B e antigen seroconversion and hepatitis B virus DNA <105 copies/mL were similar between the two groups of patients [9/29 (31.0%) vs. 2/24 (8.3%), respectively, P = 0.09]. At week 72, 10 of the 29 patients (34.5%) treated with 48 weeks of pegylated-interferon-alpha-2a compared with two of the 24 patients (8.3%) treated with 24 weeks of pegylated-interferon-alpha-2b had sustained virological response (P = 0.04). By logistic analysis, 48 weeks of pegylated-interferon- alpha-2a was independently associated with sustained virological response (P = 0.04 adjusted hazards-ratio 9.37). Conclusion: Further studies are required to determine the optimal duration of therapy with pegylated interferons in chronic hepatitis B. © 2006 Blackwell Publishing Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/84484
ISSN
2014 Impact Factor: 5.727
2013 SCImago Journal Rankings: 2.609
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorHui, CKen_HK
dc.contributor.authorLai, LSWen_HK
dc.contributor.authorLam, Pen_HK
dc.contributor.authorZhang, HYen_HK
dc.contributor.authorFung, TTen_HK
dc.contributor.authorLai, STen_HK
dc.contributor.authorWong, WMen_HK
dc.contributor.authorLo, CMen_HK
dc.contributor.authorFan, STen_HK
dc.contributor.authorLeung, Nen_HK
dc.contributor.authorLau, GKKen_HK
dc.date.accessioned2010-09-06T08:53:30Z-
dc.date.available2010-09-06T08:53:30Z-
dc.date.issued2006en_HK
dc.identifier.citationAlimentary Pharmacology And Therapeutics, 2006, v. 23 n. 8, p. 1171-1178en_HK
dc.identifier.issn0269-2813en_HK
dc.identifier.urihttp://hdl.handle.net/10722/84484-
dc.description.abstractBackground/aim: Although 48-week therapy with pegylated-interferons has been shown to be effective for the treatment of chronic hepatitis B virus infection, the efficacy of a shorter duration of therapy with pegylated interferons is unknown. Method: We reviewed 53 hepatitis B e antigen positive Chinese patients treated with 48 weeks of pegylated interferon alpha-2a or 24 weeks of pegylated interferon alpha-2b. Sustained virological response was defined as hepatitis B e antigen seroconversion and hepatitis B virus DNA <105 copies/mL at week 72. Results: Twenty-nine patients were treated with 48 weeks of pegylated-interferon-alpha-2a and 24 patients with 24 weeks of pegylated-interferon-alpha-2b. At the end-of-therapy, hepatitis B e antigen seroconversion and hepatitis B virus DNA <105 copies/mL were similar between the two groups of patients [9/29 (31.0%) vs. 2/24 (8.3%), respectively, P = 0.09]. At week 72, 10 of the 29 patients (34.5%) treated with 48 weeks of pegylated-interferon-alpha-2a compared with two of the 24 patients (8.3%) treated with 24 weeks of pegylated-interferon-alpha-2b had sustained virological response (P = 0.04). By logistic analysis, 48 weeks of pegylated-interferon- alpha-2a was independently associated with sustained virological response (P = 0.04 adjusted hazards-ratio 9.37). Conclusion: Further studies are required to determine the optimal duration of therapy with pegylated interferons in chronic hepatitis B. © 2006 Blackwell Publishing Ltd.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd. The Journal's web site is located at http://www.blackwellpublishing.com/journals/APTen_HK
dc.relation.ispartofAlimentary Pharmacology and Therapeuticsen_HK
dc.rightsAlimentary Pharmacology and Therapeutics. Copyright © Blackwell Publishing Ltd.en_HK
dc.title48 Weeks pegylated interferon alpha-2a is superior to 24 weeks of pegylated interferon alpha-2b in achieving hepatitis B e antigen seroconversion in chronic hepatitis B infectionen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0269-2813&volume=23&issue=8&spage=1171&epage=1178&date=2006&atitle=48+weeks+pegylated+interferon+alpha-2a+is+superior+to+24+weeks+of+pegylated+interferon+alpha-2b+in+achieving+hepatitis+B+e+antigen+seroconversion+in+chronic+hepatitis+B+infectionen_HK
dc.identifier.emailLo, CM: chungmlo@hkucc.hku.hken_HK
dc.identifier.emailFan, ST: stfan@hku.hken_HK
dc.identifier.authorityLo, CM=rp00412en_HK
dc.identifier.authorityFan, ST=rp00355en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1365-2036.2006.02887.xen_HK
dc.identifier.pmid16611278en_HK
dc.identifier.scopuseid_2-s2.0-33646860152en_HK
dc.identifier.hkuros116846en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-33646860152&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume23en_HK
dc.identifier.issue8en_HK
dc.identifier.spage1171en_HK
dc.identifier.epage1178en_HK
dc.identifier.isiWOS:000236392800016-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridHui, CK=35082057900en_HK
dc.identifier.scopusauthoridLai, LSW=12769869000en_HK
dc.identifier.scopusauthoridLam, P=16151746100en_HK
dc.identifier.scopusauthoridZhang, HY=8965962000en_HK
dc.identifier.scopusauthoridFung, TT=13612072400en_HK
dc.identifier.scopusauthoridLai, ST=7402937038en_HK
dc.identifier.scopusauthoridWong, WM=7403972413en_HK
dc.identifier.scopusauthoridLo, CM=7401771672en_HK
dc.identifier.scopusauthoridFan, ST=7402678224en_HK
dc.identifier.scopusauthoridLeung, N=26643107200en_HK
dc.identifier.scopusauthoridLau, GKK=7102301257en_HK
dc.identifier.citeulike571350-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats